In a sign of life for the digital therapeutics industry, Click Therapeutics has received FDA clearance with its treatment for ...

Trump signs EO on drug pricing, supports PhRMA reforms for Medicare negotiations timeline, calls for Canadian drug imports, ...

A bipartisan group of 39 state attorneys general is calling on congressional leadership to pass a bill that would prohibit ...

The Johnson & Johnson CEO subtly but assertively criticized the Trump administration’s plans for pharmaceutical tariffs, ...

Attovia Therapeutics is turning fundraising announcements into an annual tradition. In June 2023, the San Carlos, CA-based ...

Boston and Dublin biotech Mural Oncology is laying off nearly all of its employees and ending clinical development of its ...

The centerpiece of Bristol Myers Squibb’s $13 billion MyoKardia acquisition failed a Phase 3 study meant to expand the ...

Sanofi's amlitelimab fails Phase 2 asthma trial at highest dose, but company sees path forward based on medium dose results in specific patient subgroup ...

A US trade probe into pharmaceuticals is underway. And it’s hitting many of the key aspects of the supply chain.

Merck licenses Cyprumed's oral drug delivery platform in $493M deal to develop oral peptide formulations, potentially for GLP-1 drugs.

Roche devastated the Angelman syndrome community in 2023, when it ended clinical development of rugonersen, a treatment candidate for the rare neurodevelopmental condition ...

The FDA has permitted eGenesis to begin a clinical trial of a dialysis-like system that involves using a gene-edited pig liver outside of the body. It’s the second formal study ...